Evidence map›Paper›PMID 12177807›Full record

ArticleBritish journal of cancer2002

Integrin alpha(v)beta6-associated ERK2 mediates MMP-9 secretion in colon cancer cells.

X Gu, J Niu, D J Dorahy, R Scott, M V Agrez

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  15. Article
  16. Article
  17. Article
  18. Role of integrins in regulating proteases to mediate extracellular matrix remodeling.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2012
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

X GuNewcastle Bowel Cancer Research Collaborative, Hunter Medical Research Institute, John Hunter Hospital and The University of Newcastle, NSW 2308, Australia.
J Niu
D J Dorahy
R Scott
M V Agrez
John Hunter Hospital · AUUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is general consensus that matrix metalloproteinases are involved in tumour progression. We show herein that inhibition of integrin alpha(v)beta6 expression in colon cancer cells suppresses MMP-9 secretion. This integrin-mediated event is dependent upon direct binding between the beta6 integrin subunit and extracellular signal-regulated kinase 2. Targetting either beta6 or its interaction with extracellular signal-regulated kinase in order to inhibit matrix metalloproteinase activity may offer a useful therapeutic approach in preventing growth and spread of colon cancer.

Indexed as

Antigens, NeoplasmBinding SitesColonic NeoplasmsHumansIntegrinsMatrix Metalloproteinase 9Mitogen-Activated Protein Kinase 1Tumor Cells, CulturedAntigens, Neoplasmintegrin alphavbeta6IntegrinsMatrix Metalloproteinase 9Mitogen-Activated Protein Kinase 1

Identifiers

PMID12177807
PMCPMC2364215
OpenAlexW1599554492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.